Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEME	NT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Core Oncology, Inc		
Application No./Patent No.: 10/828,539	Filed/Issue Date: April 20, 2004	
Entitled: Echogenic Medical Device		
Core Oncology, Inc (Name of Assignee)	a Corporation (Type of Assignee, e.g., corporation, partnership, universi	ty, government agency, etc.)
states that it is: 1. the assignee of the entire right, title, and interes	st; or	
2. an assignee of less than the entire right, title an (The extent (by percentage) of its ownership int		
in the patent application/patent identified above by vir	tue of either:	
 A. An assignment from the inventor(s) of the patern in the United States Patent and Trademark Officion OR B. A chain of title from the inventor(s), of the patern 	e at Reel, Frame, or for which a	copy thereof is attached.
The document was recorded in the Unite	To: Mills Biopharmaceuticals, Inc. ed States Patent and Trademark Office at, or for which a copy thereof is attached	
	To: Coloplast A/S ad States Patent and Trademark Office at, or for which a copy thereof is attach	ed.
3. From: Coloplast A/S	To: Mills Biopharmaceuticals, Inc	
	, or for which a copy thereof is attach	ned.
Additional documents in the chain of title are	listed on a supplemental sheet.	
As required by 37 CFR 3.73(b)(1)(i), the document was, or concurrently is being, submitted for recordatio [NOTE: A separate copy (i.e., a true copy of the of Division in accordance with 37 CFR Part 3, to 302.08]	in pursuant to 37 CFR 3.11.	ted to Assignment
The undersigned (whose title is supplied below) is aut	thorized to act on behalf of the assignee.	110/2008
Signature	400	Date
Chris Nicholson		6) 926-2301 lephone Number
Printed or Typed Name Chief Financial Officer, Core Oncology, Inc.	i ei	ehiona iranibai
Title		

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Pelent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Supplemental Sheet to Statement Under 37 CFR 3.73(b): Additional documents in the chain of title:

Patent Application No. 10/828,539 Filing Date: April 20, 2004

4. From: Mills Bi	opharmaceuticals, Ir	nc. To: Core Oncology, Inc.
The document	was recorded in the United	d States Patent and Trademark Office at
1 019399	_, Frame 0589	or for which a copy thereof is attached.
5. From:		To:
The document	was recorded in the United	d States Patent and Trademark Office at
Reel	, Frame	or for which a copy thereof is attached.
6. From:		То:
The document	was recorded in the United	States Patent and Trademark Office at
Reel	. Frame	or for which a copy thereof is attached.